Filtered By:
Drug: Colcrys
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 87 results found since Jan 2013.
Effect of Treatment with Colchicine after Acute Coronary Syndrome on Major Cardiovascular Events: A Systematic Review and Meta-Analysis of Clinical Trials
CONCLUSION: Colchicine has shown some molecular and clinical promising results in ACS patients. The lack of effect of colchicine on MI and all-cause mortality can be partly attributed to the limitations of previous studies. Since colchicine is an inexpensive and easy-to-access drug that has shown to be safe in low-dose regimens in the clinical setting; it would be worthy that future large-scale well-designed clinical trials address this issue by resolving the limitations of previous investigations.PMID:35495414 | PMC:PMC9020977 | DOI:10.1155/2022/8317011
Source: Atherosclerosis - May 2, 2022 Category: Cardiology Authors: Erfan Razavi Akam Ramezani Asma Kazemi Armin Attar Source Type: research
Intravital Imaging Reveals the Ameliorating Effect of Colchicine in a Photothrombotic Stroke Model via Inhibition of Neutrophil Recruitment
In conclusion, we have established an intravital strategy to directly investigate pathophysiology in the ischemic border zone, and found that colchicine administration in the acute phase of ischemic stroke is a potential novel therapeutic strategy.
Source: Translational Stroke Research - April 20, 2022 Category: Neurology Source Type: research
Immune Pathways in Etiology, Acute Phase, and Chronic Sequelae of Ischemic Stroke
Circ Res. 2022 Apr 15;130(8):1167-1186. doi: 10.1161/CIRCRESAHA.121.319994. Epub 2022 Apr 14.ABSTRACTInflammation and immune mechanisms are crucially involved in the pathophysiology of the development, acute damage cascades, and chronic course after ischemic stroke. Atherosclerosis is an inflammatory disease, and, in addition to classical risk factors, maladaptive immune mechanisms lead to an increased risk of stroke. Accordingly, individuals with signs of inflammation or corresponding biomarkers have an increased risk of stroke. Anti-inflammatory drugs, such as IL (interleukin)-1β blockers, methotrexate, or colchicine, r...
Source: Atherosclerosis - April 14, 2022 Category: Cardiology Authors: Matthias Endres Maria A Moro Christian H Nolte Claudia Dames Marion S Buckwalter Andreas Meisel Source Type: research
Is Colchicine a New Game-Changer in Patients With Acute Coronary Syndrome?
This report is a detailed understanding and an in-depth interpretation of the colchicine cardiovascular outcomes trial (COLCOT) that has taken place in recent years. It is a secondary quantitative study that has reviewed studies discussing the role of colchicine in myocardial infarction, inflammation, ST-elevation myocardial infarction, and in general, acute coronary syndrome (ACS). Different trials statistically proved colchicine's role in ACS by lowering the levels of high c-reactive protein, decreasing low attenuation plaque volume, and stabilizing plaque. Hence, in other words, it has been revealed that this drug has p...
Source: Atherosclerosis - April 11, 2022 Category: Cardiology Authors: Abdul Q Nawabi Warda Hassan Lijuan Chen Naveed Shaikh Kiran Abbas Fatima T Zehra Source Type: research
Colchicine for Patients With Coronary Artery Disease: A Systematic Review and Meta-analysis
In conclusion, colchicine is associated with a lower risk of acute myocardial infarction, stroke, and coronary revascularization. However, there is some increased risk of gastrointestinal adverse events with the use of colchicine.
Source: Journal of Cardiovascular Pharmacology - April 1, 2022 Category: Cardiology Tags: Review Article Source Type: research
Colchicine may become a new cornerstone therapy for coronary artery disease: a meta ‐analysis of randomized controlled trials
AbstractPurposeColchicine is an ancient anti-inflammatory drug. In recent years, an increasing number of studies have shown that colchicine improves the prognosis of patients with coronary artery disease (CAD), while other studies have reported the opposite. The aim of this study was to evaluate the relative efficacy and safety of colchicine in treating CAD.MethodsPubMed, EMBASE, the Cochrane Library, and ClinicalTrials.gov were searched from inception to 20 October 2020 for randomized controlled trials (RCTs) comparing colchicine and placebo in patients with CAD. The primary outcomes were the primary composite outcomes of...
Source: Clinical Rheumatology - February 9, 2022 Category: Rheumatology Source Type: research
Therapeutic Implications of NLRP3-Mediated Inflammation in Coronary Artery Disease
Atherosclerosis is considered a chronic, inflammatory disease responsible for more than 15% of all global deaths, secondary to its complications of myocardial infarction, vascular disease, and stroke. Current treatment regimens consist of lipid-lowering pharmaceuticals, control of risk factors, and prevention of plaque rupture and thrombosis with antiplatelet agents. However, a significant burden on society remains due to the morbidity and mortality of coronary artery disease despite our best practices. In addition to dyslipidemia and hemostasis, inflammation has now moved to the proverbial forefront as the remaining obsta...
Source: Cardiology in Review - February 4, 2022 Category: Cardiology Tags: Review Articles Source Type: research
Effects of colchicine on major adverse cardiac events in next 6-month period after acute coronary syndrome occurrence; a randomized placebo-control trial
CONCLUSION: The addition of colchicine to standard medical therapy in ACS patients significantly reduces MACE occurrence and improves survival rate over the time.PMID:34876021 | DOI:10.1186/s12872-021-02393-9
Source: Atherosclerosis - December 8, 2021 Category: Cardiology Authors: Mehdi Akrami Peyman Izadpanah Mehdi Bazrafshan Unes Hatamipour Navid Nouraein Hamed Bazrafshan Drissi Alireza Manafi Source Type: research
Colchicine-new horizons for an ancient drug
Eur J Intern Med. 2021 Oct 14:S0953-6205(21)00332-0. doi: 10.1016/j.ejim.2021.10.002. Online ahead of print.ABSTRACTColchicine is an old, inexpensive, and relatively safe anti-inflammatory drug traditionally used in gout and over the last 50 years in familial Mediterranean fever. A search of all high-hierarchy studies (randomized controlled trials [RCTs], systematic reviews and meta-analysis of RCTs) over the last 20 years revealed myriad other evidence-based applications. Colchicine seems efficacious in the treatment of acute pericarditis and prevention of recurrences and the prevention of postcardiac injury syndrome and ...
Source: European Journal of Internal Medicine - October 18, 2021 Category: Internal Medicine Authors: Ami Schattner Source Type: research
